meta|Evidence - COVID-19
click on circles to display study description...
tofacitinib (n=144) vs. placebo (n=145)
randomized controlled trial low risk of bias
tofacitinib at a dose of 10 mg twice daily
for up to 14 days or until hospital discharge
placebo
COVID 19 hospitalized
patients 18 years of age or older who had laboratory-confirmed SARS-CoV-2 infection as determined on RT-PCR assay before randomization, who had evidence of Covid-19 pneumonia on radiographic imaging, and who had been hospitalized for less than 72 hours.The main exclusion criteria were the use of noninvasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) on the day of randomization, a history of thrombosis or current thrombosis, known immunosuppression, and any current cancer for which the patient was receiving active treatment.
double blind
15 sites in Brazil
tofacitinib (n=50) vs. standard of care (n=50)
randomized controlled trial risk of bias NA
COVID-19 mild to moderate
powered by vis.js Network